2 No-Brainer Dividend Stocks to Buy in May
Dividend stocks have delivered the bulk of U.S. stock market returns since 1960. AT&T and Pfizer stand out as incredible bargains for income and value investors alike.
This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream
Shares of Pfizer offer a 6% dividend yield at recent prices. The pharmaceutical giant has raised its quarterly payout for 15 consecutive years.
Pfizer agrees to settle over 10K lawsuits linking Zantac to cancer
The lawsuits were filed in state courts nationwide, but the agreements don't completely resolve Pfizer's exposure to claims linking Zantac and cancer.
Pfizer: A 6% Yield And At 10-Year Lows
Pfizer's stock has experienced significant fluctuations in the past 4 years, with opportunities for investors to buy low and sell high. The market has driven Pfizer's price to a 10-year low. Pfizer...
Pfizer reports patient death in Duchenne gene therapy study
A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker to...
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Biopharma giant Pfizer Inc. NYSE: PFE has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to its...
Here's Why Pfizer (PFE) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Pfizer Stock Blasted More Than 6% Higher Today
The pharmaceutical giant published its first-quarter results.
Pfizer Stock Gets Boost From Better-Than-Expected Earnings
Pfizer (PFE) shares rose Wednesday after first-quarter earnings and revenue fell less than expected, with the decline partially offset by sales growth in the company's non-COVID-related products.
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare ...
Pfizer revenues fall 19% due to lower COVID-related product demand
US pharmaceutical multinational Pfizer Inc (NYSE:PFE, ETR:PFE)'s first-quarter 2024 revenues stood at $14.9 billion, reflecting a 19% operational decline year over year, primarily due to decreased ...
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
The results come as Pfizer tries to regain its footing after the rapid decline of its Covid business.
Pfizer first-quarter results top estimates, drugmaker boosts full-year profit outlook
Pfizer Inc. shares PFE, -0.08% gained 1.5% premarket on Wednesday after the company reported first-quarter profit and sales that beat analyst expectations, boosted by strong sales of its Vyndaqel f...
Pfizer's 44% Decline In Profits Still Tops Estimates—Stock Bounces From Decade Low
Pfizer comfortably beat expectations in its quarterly earnings report Wednesday morning, as the American pharmaceutical giant attempts to regain its footing as the COVID-19 pandemic subsides.
Related Companies